FFAR4 and metabolic syndrome: Interestingly, GW9508 treatment significantly reduced MetS-increased fasting glucose, cholesterol, and free fatty acids (FFA) in mice, suggesting that GW9508 as a GPR40/GPR120 agonist improves MetS.